Scienture starts commercial sales, fulfillment of first orders of Arbli

Scienture (SCNX) announced the start of commercial sales and fulfillment of the first customer orders for Arbli Oral Suspension, 10 mg/mL, marking an important milestone in the Company’s growth as it begins to bring this differentiated product to market. Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. As part of its commercial campaign, Scienture is executing targeted outreach for Arbli to healthcare professionals and has finalized PBM-Led GPO agreements for expanded commercial coverage and formulary access.